Related Experiment Video
Updated: Aug 16, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
The Neuroprotective Effect of Byu d Mar 25 in LPS-Induced Alzheimer's Disease Mice Model
Lan Liu1,2,3, Yongcang Zhang1, Liang Tang4
1Medical College, Tibet University, Lhasa, Tibet 850000, China.
Abstract:
Inflammatory factors play an important role in the pathogenesis of Alzheimer's disease (AD). Byu d Mar 25 (BM25) has been suggested to have protective effects in the central nervous system. However, the effect of BM25 on AD has not been determined. This study aims to investigate the neuroprotective effect of BM25 in AD. A total of 40 AD model mice were randomly assigned to the following five groups (n = 8 per group): the AD + NS group, the AD + donepezil group, and three AD + BM25 groups treated with either 58.39 mg/kg (AD + BM25-L), 116.77 mg/kg (AD + BM25-M), or 233.54 mg/kg BM25 (AD + BM25-H). The Morris water maze test was performed to assess alterations in spatial learning and memory deficits. Nissl staining was performed to detect Nissl bodies and neuronal damage. The expression of IL-1β and TNF-α was evaluated by ELISA. The protein expression of P-P38, P38, P-IκBα, caspase 1, COX2, and iNOS was determined by western blotting. The expression of Aβ, p-Tau, and CD11b was measured by immunohistochemistry. The mRNA expression levels of IL-1β, TNF-α, COX2, and iNOS were measured by qRT-PCR. Spatial memory significantly improved in the AD + BM25-M and AD + BM25-H groups compared with the AD + NS group (p < 0.05). The expression of Aβ and p-Tau significantly decreased in the AD + BM25-M and AD + BM25-H groups (p < 0.05). The neuron density and hierarchy and number of pyramidal neurons significantly increased in the AD + BM25-M and AD + BM25-H groups (p < 0.05). In addition, the expression levels of CD11b, IL-1β, TNF-α, COX2, iNOS, caspase 1, p-IκBα, and p-P38 significantly decreased in the AD + BM25-M and AD + BM25-H groups (p < 0.05). In conclusion, our findings suggest that BM25 may exert anti-inflammatory and neuroprotective effects in AD model mice by suppressing the activity of microglia and inhibiting the phosphorylation of IκBα and p38 MAPK.
Insights
BM25 demonstrates significant neuroprotective effects in Alzheimer's disease (AD) mouse models. It improves spatial memory and reduces amyloid-beta and p-Tau levels by suppressing inflammation and microglial activity.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Inflammatory factors are implicated in Alzheimer's disease (AD) pathogenesis.
- Byu d Mar 25 (BM25) shows potential central nervous system protective effects.
- The efficacy of BM25 in AD treatment remains uninvestigated.
Purpose of the Study:
- To investigate the neuroprotective potential of BM25 in an AD mouse model.
- To evaluate BM25's impact on cognitive function, neuropathology, and inflammatory markers in AD.
Main Methods:
- Alzheimer's disease model mice were treated with varying doses of BM25.
- Cognitive function was assessed using the Morris water maze test.
- Neuroinflammation markers (IL-1β, TNF-α), AD pathology markers (Aβ, p-Tau), and signaling pathways (MAPK) were analyzed using ELISA, Western blotting, immunohistochemistry, and qRT-PCR.
Main Results:
- BM25 treatment significantly improved spatial memory in AD mice.
- BM25 reduced amyloid-beta (Aβ) and phosphorylated Tau (p-Tau) levels.
- BM25 decreased neuroinflammatory markers (IL-1β, TNF-α, COX2, iNOS), microglial activation (CD11b), and key signaling molecules (caspase 1, p-IκBα, p-P38).
Conclusions:
- BM25 exhibits significant anti-inflammatory and neuroprotective effects in AD model mice.
- BM25 exerts its effects by suppressing microglial activity and inhibiting the IκBα and p38 MAPK signaling pathways.
- BM25 represents a potential therapeutic agent for Alzheimer's disease.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018